About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven commercially available products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Gilead Worldwide

Gilead maintains research, development or manufacturing facilities in the United States and Europe. In the United States, operations are based in Foster City and San Dimas, California and Durham, North Carolina. European operations are based in Cambridge, United Kingdom; Dublin, Ireland and Paris, France. Additionally, sales and marketing organizations are located in the following cities: Athens, Greece; Cambridge, United Kingdom; Lisbon, Portugal; Madrid, Spain; Melbourne, Australia; Milan, Italy; Munich, Germany and Paris, France.

Marketed Products

Gilead takes great pride in its unique portfolio of therapeutics, designed to advance the care of patients suffering from life-threatening infectious diseases. Currently, our portfolio includes seven marketed products:

• Truvada® (emtricitabine and tenofovir disoproxil fumarate)


• Viread® (tenofovir disoproxil fumarate)


• Emtriva® (emtricitabine)


• AmBisome® (amphotericin B) liposome for injection


• Hepsera® (adefovir dipivoxil)


• Tamiflu® (oseltamivir phosphate)


• Vistide® (cidofovir injection)

Discovery and Development

At Gilead, we employ the most advanced scientific tools to develop therapeutics for the treatment of infectious diseases.

Based upon recent advances in molecular and cellular biology, researchers understand viral replication better than ever before. At Gilead, we apply this knowledge to study the sites of viral replication and to explore how a virus might mutate to become resistant to treatments. This enables us to better understand the profiles of the antivirals we develop - both alone and in combination with other antivirals - and to provide physicians with insight into which therapeutics or combinations may produce optimal benefits.

Throughout the process of designing novel antiviral therapeutics, Gilead biologists and chemists work together to examine key viral enzymes that are required for the replication of pathogenic viruses in host cells. With their detailed understanding of the structure and function of these viral enzymes or targets, the goal of Gilead researchers is to design and synthesize new antiviral inhibitors with more favorable characteristics, such as enhanced potency, improved resistance profile, prolonged duration of activity and better selectivity.

For more information, visit the Gilead website here.